Novavax (NVAX) ended the recent trading session at $10, demonstrating a -1.19% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.92%. At ...

在一名临床试验参与者发生严重不良事件後，Novavax(NVAX.US)遭美国食品和药物管理局暂停其实验性流感疫苗的开发，该股股价周三下挫20%。

10月16日｜诺瓦瓦克斯(NVAX.US) 盘前大跌逾31%，美国食品药品监督管理局（FDA）暂时搁置公司新冠流感疫苗临床试验申请，对此，诺瓦瓦克斯医药表示，临床暂停是因为单个CIC 2期试验参与者发生了严重的运动神经病变事件的自发报告。

智通财经APP注意到，周三美股盘前，诺瓦瓦克斯医药(NVAX.US)股价一度跌近30%，此前美国FDA暂停了其COVID-19和流感联合疫苗以及独立流感候选疫苗的新药申请，理由是一名试验参与者出现严重不良事件。截至发稿，诺瓦瓦克斯医药跌16.83%， ...

智通财经APP获悉，周三，诺瓦瓦克斯医药 (NVAX.US)股价大幅下跌，截至发稿，该股跌超19%，报10.16美元。消息面上，美国食品药品监督管理局 (FDA)暂停了该公司计划进行的流感疫苗临床试验，临床暂停是因为单个CIC ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.

A single adverse event halts trials for Novavax's COVID-19 and influenza combination vaccine, raising concerns but leaving ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

周三，诺瓦瓦克斯医药(NVAX.US)股价大幅下跌，截至发稿，该股跌超19%，报10.16美元。消息面上，美国食品药品监督管理局(FDA)暂停了该公司计划进行的流感疫苗临床试验，临床暂停是因为单个CIC2期试验参与者发生了严重的运动神经病变事件的自发报告。

Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...